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Abstract
Background—Small molecular CCR5 inhibitors represent a new class of drugs for treating
HIV-1 infection. The evaluation of the primary resistance mutations associated with entry
inhibitors during HIV-1 perinatal transmission is required because they may have a profound
impact on the clinical management in MTCT.
Objectives—To evaluate the primary resistance mutations to maraviroc and vicriviroc during
perinatal transmission and analyze the sensitivity of Env derived from mother–infant pairs to
maraviroc.
Study design—Nine MIPs infected by subtype C HIV-1 were recruited to analyze the
prevalence and transmission of primary resistance mutations to maraviroc and vicriviroc.
Moreover, Env derived from six MIPs were employed to construct provirus clones and to analyze
the sensitivity to maraviroc.
Results—Mutations A316T, conferring partial resistance to maraviroc, T307I and R315Q, both
conferring partial resistance to vicriviroc are prevalent in mother and infant cohorts, indicating the
transmission of primary resistance mutations during HIV-1 perinatal transmission. However, the
mutations of acutely infected mothers seem to directly transmit to their corresponding infants,
while some mutations at low frequency of chronically infected mothers would be lost during
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transmission. Moreover, provirus clones derived from acutely infected MIPs are less susceptible to
maraviroc than those from chronically infected MIPs.
Conclusions—Our study suggests that the transmission mode of primary resistance mutations
and the sensitivity to maraviroc are dependent on infection status of MIPs either acutely or
chronically infected. These results may indicate that higher dose of maraviroc could be needed for
treatment of acutely infected MIPs compared to chronically infected MIPs.
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1. Background
Mother-to-child transmission (MTCT) of the human immunodeficiency virus type 1 (HIV-1)
remained the major route of infection for children in endemic regions and more than 90% of
the infected children acquired HIV-1 from their mothers.1,2 This is especially significant in
sub-Saharan Africa where most of the new perinatal transmission cases have been reported.3
Moreover the most prevalent HIV-1 subtype which is transmitted perinatally in the setting is
subtype C, the much less well characterized HIV-1 subtype.4
Antiretroviral drugs (ARVs) for HIV-1-infected pregnant women and their infants are highly
effective in reducing MTCT of HIV-1, especially when the WHO guidelines for the
prevention of MTCT of 2006 and 20105,6 recommend complex antiretroviral prophylaxis to
replace single dose nevirapine (sdNVP), a non-nucleoside reverse transcriptase inhibitor
(NNRTI).3,7 However, concerns have been raised about the public health implications of the
emergence of resistance to antiretroviral drugs.8–11
Small molecular CCR5 inhibitors represent a new class of drugs for treating HIV-1
infection, by binding to a hydrophobic cavity located between the transmembrane domains
of CCR5, inducing conformational changes in CCR5 and then inhibiting HIV-1 entry
allosterically.12,13 Thus far, three CCR5 antagonists (maraviroc, vicriviroc and aplaviroc)
have been shown to inhibit virus replication in humans.14 Although vicriviroc and aplaviroc
have been tested in clinical trials and were not pursued because of sub-optimal efficacy and
liver toxicity respectively,15 maraviroc was approved by the FDA in 2007 and has been
utilized as a salvage therapy for multi-drug resistant patients with R5 tropic virus,14,16,17
which harbored the potential clinical use to prevent MTCT more efficiently. Drug
resistance-associated mutations (DRAMs) have been reported in the V3 region of the env
against maraviroc18 and vicriviroc.19,20 Primary mutations associated with resistance to
maraviroc and vicriviroc are also found to be prevalent in adult therapy naive patients.21,22
However, the prevalence and transmission of primary mutations to HIV-1 entry inhibitors-
maraviroc and vicriviroc during MTCT are unclear, and both may have a profound impact
on the clinical management of maraviroc.
Guo et al. Page 2
J Clin Virol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Objective
The study aims to evaluate the presence and transmission of resistance-associated mutations
to maraviroc and vicriviroc during MTCT, and to analyze the sensitivity of env derived from
Mother–Infant Pairs (MIPs) to maraviroc.
3. Study design
3.1. Patient information
Archived nine Mother–Infant Pairs (MIPs) 1084, 1984, 2617, 2669, 2873, 1449, 2660, 834
and 2953 from Zambia were available for this study and described previously.23,24 The
mothers of six MIPs (pairs 1084, 1984, 2617, 2669, 1449 and 2873) were found to be
infected at delivery and their infants were determined by PCR to be infected at either 2
months (pairs 2617, 2669, 1449 and 2873) or 4 months (1084 and 1984) after birth. These
six MIPs were defined as the chronically transmitted MIPs. For other MIPs (pairs 834, 2660
and 2953), mothers and infants were found to have seroconverted at the same follow-up time
point and at 4, 18 and 11 months after birth, respectively. They were defined as acutely
infected MIPs. For the chronically infected MIPs, maternal samples collected at delivery and
infant samples collected at the first postpartum HIV-1 PCR-positive time point were defined
as baseline specimens. For acutely infected MIPs, the baseline specimens were obtained at
the time of seroconversion. The baseline HIV-1 serological status of the mother was
determined by two rapid assays, Capillus (Cambridge Biotech, Ireland) and Determine
(Abbott laboratories, USA). Positive serological results were confirmed by
immunofluorescence assay (IFA) as previously described.25
3.2. Cloning and sequencing of env derived from patients
To obtain the proviral HIV-1 env gene, genomic DNA was extracted from uncultured
peripheral blood mononuclear cells (PBMC) for all subjects except for mother 1084. For
mother 1084, env gene was amplified from placenta tissue since PBMC was not available.
Nested PCR was used to amplify a 1100 bp fragment spanning the V1-V5 region of env as
described previously.24 Amplified fragments were cloned into the pGEM-T easy vector
(Promega) and sequenced in both directions with dideoxy terminators (ABI BigDye Kit). A
total of 20–40 clones were sequenced for each sample to obtain a representative
measurement for the diversity of the viral population genotypes. A maximum likelihood
(ML) tree was constructed for each transmission pair, including the V1-V5 region of env
gene amplified from nine MIPs and two unrelated subtype C reference sequences from the
Los Alamos HIV Sequence Database as outgroup sequences to root the Trees.26 Subtyping
analysis indicated that the clones sequenced of all the MIPs corresponded to HIV-1 subtype
C, except for MIP 1449, which were subtype A/C recombination.23,24 The primary isolates
from these MIPs studied here were found to exclusively use CCR5 as a co-receptor, exhibit
macrophage-tropism, and do not infect T-cell lines or cause syncytia in vitro.23,24 The
analysis of resistance-associated mutations to maraviroc and vicriviroc included: (i) A316T
and I323V,18 and (ii) K305R, S306P, T307, 315Q, F318I, T320R, and G321E,19,20
respectively.
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3.3. Generation of recombinant proviral expression constructs
The patient V1–V5 region of env gene was cloned into an Env expression vector pSRH
NLA/S/Av (kindly provided by Dr. Eric Hunter, Emory University).27 All the patient-
derived chimeric Env expression constructs were first screened for biological function using
the fusion assay.28 Between 30% and 70% of the selected clones were biologically
functional. Finally, four to eight functional envelope constructs derived from patients were
subcloned into a proviral expression vector NL4.3ΔEnvEGFP (kindly provided by Dr.
Miguel E. Quinones-Mateu, Case Western Reserve University), resulting in the infectious
molecular clone plasmids. To eliminate the possibility that the selected clones for the
analysis could be outliers, we then calculated the divergence for each selected clone of the
MIP as the genetic distance between any sequence and the most recent common ancestor
(MRCA) of the total previously analyzed archived virus sequences. It showed that
divergence from each selected Env is within the range of the characterized population, and
no outlier of divergence was used in our analysis.29
3.4. Cells and cell cultures
TZM-bl, COS-1 and 293T cells were maintained in Dulbecco's Modified Eagle's Medium
(DMEM) with 10% fetal bovine serum (FBS), penicillin (50 U/ml) and streptomycin (50 μg/
ml).
3.5. Virus stocks
The chimeric viruses bearing patient-derived Env V1-V5 region were produced by
transfecting proviral constructs into 293T cells. Culture supernatants were harvest at 48 h
post-transfection, and stored at −80 °C. The p24 content of each virus stock was determined
using HIV-1 p24 ELISA kit (Perkin-Elmer Life Sciences, Inc.).
3.6. Assay of sensitivity to CCR5 antagonists
The drug susceptibility assay was performed using TZM-bl cells as previously described.20
Briefly, 2 × 104 TZM-bl cells/well were seeded into 96-well plates and incubated at 37 °C
overnight. The next day, serial 2-fold dilutions of maraviroc (ranging from 32 nM to 0.125
nM) were added to wells 1 h prior to the addition of 10 ng of p24 of each virus. Plates were
incubated for another 48 h and luciferase activity was analyzed by adding 50 μl of
SteadyGlo™ luciferase assay buffer according to the manufacturer's instructions (Promega,
Madison, WI).
4. Results
4.1. Characteristics of the nine MIPs
As summarized in Table 1, the maternal age at delivery was between 19 and 31 years. The
mode of delivery of all MIPs was vaginal except MIP 2617, which was cesarian section. The
mothers of chronically infected MIPs were known to be HIV-1 positive at the time of
delivery and are likely to have acquired HIV-1 infection heterosexually, but their infants
were HIV-1 negative at birth, suggesting the infants were infected either intrapartum or
postpartum. For the acutely infected MIPs, mothers and infants were found to have
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seroconverted at the same time point after birth, suggesting the infants were infected through
breast-feeding (Table 1). All the mothers were asymptomatic without any clinical signs of
immunosuppression and the infants were all breast-fed and drug naive. Infants of pairs 2617,
2669, 2873, and 1449 were considered rapid progressors since they died within the first year
of life, due to apparent HIV-related complications (Table 1).
4.2. Analysis the primary resistance mutations to maraviroc and vicriviroc in viral
quasispecies of mothers of each MIP
Maraviroc and vicriviroc resistance-associated mutations in V3 regions of gp120 are
detailed in Fig. 1. For maraviroc, the mutations A316T and I323V have been reported to
confer partial resistance for subtype B viruses.18 For vicriviroc, mutation K305R was
reported to confer partial resistance for both subtype C and subtype G viruses.19,20
However, a number of mutations associated with vicriviroc resistance (S306P, T307I, F318I,
T320R, and G321E) were observed only in a subtype C variant.19 Mutation R315Q was
observed in a subtype G variant.20 As shown in Fig. 1, all samples of 31 Env derived from
maternal quasispecies of MIP 2617 harbor mutations T307I and R315Q. The A316T
mutation was detected in 69.2% of the samples. A316I and F318Y were the major
polymorphisms found in the V3 regions. The resistance mutations in maternal quasispecies
of other MIPs are summarized in Table 2. Similarly, mutations A316T, T307I and R315Q
were most prevalent in mother quasispecies. Mutation I323V, which also conferred partial
resistance to maraviroc, was only found in mother 1449.
4.3. Analysis the transmission of primary resistance mutations from mother quasispecies
to their corresponding infants
Maraviroc and vicriviroc mutations related to reduce susceptibility in quasispecies of infants
of each MIP are summarized in Table 2. Mutation A316T, T307I and R315Q are still
predominant in most infant viral quasispecies, indicating the primary resistance mutations
could be transmitted from mothers to infants during perinatal transmission. In the three
acutely infected MIPs, the primary resistance mutations seem to be directly transmitted from
mothers to infants. However, in the chronically infected MIPs, some of the resistance
associated mutations presented in mother quasispecies have been lost during the
transmission, such as mutation A316T and R315Q in MIP 1449, mutation K305R and T307I
in MIP 2669, and T307I in MIP 2873.
4.4. Sensitivity of proviruses harboring V1-V5 regions derived from patients to maraviroc
To better understand the impact of the primary mutations on viral sensitivity to maraviroc,
replication-competent recombinant proviruses harboring NL4-3 backbone and V1–V5
regions derived from representative four chronically and two acutely infected MIPs, were
constructed to analyze their susceptibility to maraviroc. Although most of the MIPs except
for MIP 2669 harbored one primary mutation site associated to reduce susceptibility to
maraviroc, all the proviruses remained fully susceptible to maraviroc as the complete dose
response curves were obtained (Fig. 2A–F). And no resistance to maraviroc, characterized
by a plateau at less than 90% inhibition18 was observed. The IC50 is variable among all the
MIPs (Fig. 3A). Moreover, it should be noticed that mothers and infants of acutely infected
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MIPs are less susceptible to maraviroc compared to the mothers and infants of chronically
infected MIPs by comparing IC50. (P = 0.004 and P = 0.003, respectively) (Fig. 3B).
5. Discussion
To the best of our knowledge, this is the first study that evaluates the prevalence and
transmission of the primary resistance mutations to CCR5 antagonists-maraviroc and
vicriviroc during perinatal transmission. We found a high prevalence of mutations A316T,
R315Q and R307I, conferring partial resistance to maraviroc18 and vicriviroc20 respectively,
in the viral quasispecies of Zambia pregnant women infected by subtype C HIV-1. The
mutation R315Q seems to be a specific natural polymorphism for the subtype C HIV-1, in
agreement with the recent reports.21,22 ART was available to the public sector in 2002 when
the Zambian Ministry of Health initiated an ART program at the country's two largest
hospitals, and scaled up in 2004. However, entry inhibitors are not available in the ART
therapy in Zambia.22 Therefore, the resistance associated mutations in our ARV-naive
HIV-1 infected mothers are related to naturally occurring mutations to maraviroc and
vicriviroc rather than selected and transmitted from patients with administration of entry
inhibitors.
Primary mutations were also observed in infant quasispecies, indicating they could be
transmitted during perinatal transmission. In our acutely infected MIPs, the mutations
present in mothers were found to be directly transmitted to their infants. However, in the
chronically infected MIPs, the mode of transmission is complex and variable. Some
mutations at low frequency in maternal quasispecies have been lost during perinatal
transmission. The differences may be due to a selection event in our chronically infected
MIPs while lack of viral selection occurred in our acutely infected mothers. The results are
supported by our previously phylogenetic analyses, a genetic bottleneck was observed in our
chronically infected MIPs but not in acutely infected MIPs.23,26 This lack of bottleneck
selection in acutely infected MIPs is unlikely to be due to the high viral load of the mothers
due to acute infection as the viral burden was found to be similar in the mothers for both
acute and chronic transmission.
We also analyzed the sensitivity of chronically infected MIPs and acutely infected MIPs to
maraviroc as the prevalence and transmission of primary mutations may compromise the use
of its treatment strategy. All the proviruses containing V1–V5 regions derived from
chronically and acutely infected MIPs showed fully susceptible to maraviroc. And there
seems to be no difference of IC50 between the proviruses containing A316T or I323V
mutation and the proviruses which did not harboring the mutation. The A316T and I323V
have been reported to confer partial resistance for subtype B viruses. And complete
resistance to this entry inhibitor occurs when both mutations (A316T/I323V) are present.18
However, in our study, the subtype C viruses harboring A316T or I323V mutation did not
show partial resistance to maraviroc as subtype B did. The results indicated that the genetic
background of HIV-1 subtypes may influence the mutations associated resistance to
maraviroc. This is consistent with the study which showed the three-amino-acid QAI (315–
317) deletion in the V3 region conferred the resistance phenotype for a subtype G strain.18
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It should be noted that mothers and infants of acutely infected MIPs were less susceptible to
maraviroc than chronically infected MIPs. One possible explanation is that viral
quasispecies of chronically infected mothers have been selected for effective replication in
the host and hence more sensitivity to maraviroc. However, proviruses of acutely infected
mothers did not have enough time to adapt. This supports the previous study which showed
maraviroc resistance-associated mutations may compromise viral replication in vitro.18
However, our numbers of chronically and acutely infected mothers are not sufficient and a
much larger number of subtype C infected mothers will need to be analyzed to determine if
such a pattern persists. These results nevertheless indicate that higher doses of maraviroc
would be needed for treatment of acutely infected as compared to chronically infected
individuals.
In conclusion, although the relatively small sample size, our results indicate that the natural
accumulation of polymorphisms that can generate resistance to maraviroc and vicriviroc
could be transmitted during perinatal transmission and the transmission mode of chronically
infected MIPs is more complex than acutely infected MIPs. Moreover, provirus clones
derived from acutely infected MIPs are less susceptible to maraviroc than chronically
infected MIPs. Further studies of larger sample size from other endemic regions are needed.
Nevertheless, these findings may help define the clinical management of maraviroc for the
treatment of Zambian patients infected with HIV-1 subtype C since the high prevalence and
transmission of these primary mutations during MTCT may compromise the efficiency of
maraviroc therapy.
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Fig. 1.
Analyze the primary resistance mutations to maraviroc and vicriviroc in the V3 loop of
maternal variants of MIP 2617. This alignment includes V3 sequences derived from HXB2,
subtype B, subtype C and G HIV-1 sequences reported previously, and 27 maternal variants
sequences from MIP 2617. Resistance mutations to maraviroc and vicriviroc are shown
above and numbering of amino acid position is based upon the HXB2 envelope sequence.
(a) The subtype B HIV-1 isolate was used as reference sequence of amino acid position 316
and 323. (b) The subtype C HIV-1 isolate was used as reference sequence of amino acid
position 306, 307, 318, 320, and 321. (c) The subtype G HIV-1 isolate was used as reference
sequence of amino acid position 305 and 315. Maternal samples were collected at the
delivery, indicated as m0. The number after the dash indicates the clone number. Amino
acid identity (·), insertions/deletions (∼) and substitutions are indicated.
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Fig. 2.
Susceptibility of provirus clones harboring NL4.3 backbone and V1-V5 regions derived
from MIP 834 (A), MIP 2660 (B), MIP 1084 (C), MIP 2617 (D), MIP 2669 (E), MIP 1449
(F) to maraviroc. Maraviroc was added to TZM-bl cells in concentrations ranging from
0.125 to 32 nM, incubated for 1 h. And then TZM-bl cells were infected with a standardized
input of viruses from each MIP. Data points represent percent replication in the presence of
drug relative to no drug. Maternal samples were collected at the delivery, indicated as m0.
Infant samples were collected at the time of the first HIV PCR-positive result after birth,
which for most infants was at 2 months after birth (i2), for some was at 4 months (i4) and
for some was at 6 months (i6). The number after the dash indicates the clone number. The
bars represent the SD. of the mean from three independent experiments.
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Fig. 3.
Analyze the 50% inhibitory concentrations of maraviroc (IC50 values). (A) IC50 values were
computed from the curves and plotted for maternal and infant provirus of each MIP. (B)
Comparable analysis the average IC50 of all the maternal and infant proviruses between
acutely infected MIPs and chronically infected MIPs.
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